WO2016033646A1 - Test device and method - Google Patents
Test device and method Download PDFInfo
- Publication number
- WO2016033646A1 WO2016033646A1 PCT/AU2015/050510 AU2015050510W WO2016033646A1 WO 2016033646 A1 WO2016033646 A1 WO 2016033646A1 AU 2015050510 W AU2015050510 W AU 2015050510W WO 2016033646 A1 WO2016033646 A1 WO 2016033646A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sample
- sample receiving
- test
- test strip
- indication
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5023—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures with a sample being transported to, and subsequently stored in an absorbent for analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
- A61B10/0038—Devices for taking faeces samples; Faecal examination devices
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
- G01N33/725—Haemoglobin using peroxidative activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
- G01N33/726—Devices
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0605—Metering of fluids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/06—Fluid handling related problems
- B01L2200/0647—Handling flowable solids, e.g. microscopic beads, cells, particles
- B01L2200/0668—Trapping microscopic beads
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2200/00—Solutions for specific problems relating to chemical or physical laboratory apparatus
- B01L2200/14—Process control and prevention of errors
- B01L2200/141—Preventing contamination, tampering
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/04—Closures and closing means
- B01L2300/041—Connecting closures to device or container
- B01L2300/043—Hinged closures
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/0681—Filter
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/06—Auxiliary integrated devices, integrated components
- B01L2300/069—Absorbents; Gels to retain a fluid
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/16—Surface properties and coatings
- B01L2300/161—Control and use of surface tension forces, e.g. hydrophobic, hydrophilic
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
- B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/02—Devices for withdrawing samples
- G01N1/10—Devices for withdrawing samples in the liquid or fluent state
- G01N1/12—Dippers; Dredgers
Definitions
- the present invention is generally directed to diagnostic and analytical systems for the detection of an analyte in a sample, and in particular to a test device and method applicable for this application. While the present invention will be described with respect to its application in screening for lower intestinal disorders, particularly in screening for colorectal cancer, it is to be appreciated that the invention is not restricted to this application, and that other applications are also envisaged.
- FITs Immunochemical Tests
- CRC colorectal cancer
- US Patents 7972871 and 8389287 respectively describe a testing device and collection method that addresses in part some of the above issues by simplifying the testing and collection processes.
- US Patent 8389287 describes a collection process utilising a brush or brush-like device to sample toilet bowl water from on or around the stool after defaecation. The brush can then be used to transfer the sample to a sample collection device, where it dries, thereby ensuring analyte stability during transport.
- US Patent 7972871 describes the conversion of the sample collection device into a test device by inserting an immunochemical test strip into the sample collection card.
- Reagent addition to the collection card mobilises the sample and transports it to the test strip, where anti-human haemoglobin antibodies label and immobilise any haemoglobin in the sample thereby indicating the presence or absence of faecal occult blood in the sample.
- a method for testing an analyte in a collected sample using a test device including an enclosure having at least one sample receiving port for receiving the collected sample; a test strip located within the enclosure, the test strip containing at least one reagent for detecting the analyte and for providing an indication showing a test result for the collected sample, the enclosure including a detection arrangement for allowing detection of the indication of the test strip; and a sample receiving matrix positioned behind the at least one sample receiving port and having a defined saturation capacity, the sample receiving matrix being impregnated with reagents for pre-treatment of the sample and being in liquid-conductive communication with the test strip, said method comprising: delivering one or more samples to the at least one sample collection port to saturate the sample receiving matrix such that a quantified amount of the sample is transferred to the test strip and an indication of the test result is effected.
- liquid-conductive communication shall be taken to mean that a sample collected within a solvent such as water, when applied via the sample collection port to the sample receiving matrix is capable of being in liquid-conductive communication with the test strip under sufficient conditions of hydration to enable transfer of at least part of said sample, or a component thereof, to the test strip.
- the test strip may be formed from an elongate strip of hydrophilic material.
- One end of the strip may provide a first location for sample addition (referred to as a sample receiving port), the opposing end of the strip providing a second location for the indication, such as a visual indication, showing the test result.
- the first location of the test strip may therefore be located in liquid conductive communication with the sample receiving port.
- the transferred sample may then migrate along the test strip to a downstream area of the test strip where the presence of the analyte may be indicated.
- the test device may be an extension of the test strip described in US Patent 7972871.
- the sample receiving matrix may be added onto the end of the test strip and laminated as a single web, ensuring direct contact between the sample receiving matrix and the test strip. This web may then be impregnated with the same solutions used to prepare the sample receiving matrix and test strip.
- the distance between the sample receiving matrix and the indication zone for example a visual indication zone such as a gold conjugate zone, may be varied, to ensure adequate mixing and/or rehydration of the collected sample with the dried buffer/reagents on the sample receiving matrix.
- the test strip may include, for example, an area with dried down gold- conjugated polyclonal anti-human haemoglobin (Hb) antibody downstream from the sample application area.
- a line of immobilised monoclonal anti-Hb antibody may be located further downstream on the test strip. This line captures and accumulates any gold- conjugated Ab-Hb complexes that are produced if Hb is present in the sample, to thereby produce a visible line. This line therefore provides visual confirmation of the presence of Hb in the water sample.
- other disclosing agents may be used which enable the indication to be detected, for example fluorescent dyes or particles, or magnetic particles.
- the detection of bound aggregates of Hb and the disclosing agent may be by other means, e.g. spectrometry, fluorimetry or magnetometry.
- spectrometry e.g. fluorimetry
- magnetometry e.g. magnetometry
- test strip of the present invention may therefore further include reagents which detect the pseudoperoxidase activity of haem such as a peroxidase reagent and a chromogen reagent, preferably at a distal end of the test strip and beyond the immunodetection zone, that allows for the detection of high haemoglobin (Hb) levels by providing a prominent colour reaction in the presence of haem.
- reagents which detect the pseudoperoxidase activity of haem such as a peroxidase reagent and a chromogen reagent, preferably at a distal end of the test strip and beyond the immunodetection zone, that allows for the detection of high haemoglobin (Hb) levels by providing a prominent colour reaction in the presence of haem.
- the pseudo peroxidase reaction detects the stable haem of the haemoglobin and the immunochemical reaction detects the labile globin protein.
- the use of a two stage testing procedure directed to testing for both the haem and the globin components of haemoglobin also permits differentiation of upper gastrointestinal tract bleeding from lower gastrointestinal tract bleeding. Since the globin protein of haemoglobin does not survive passage through the upper gastrointestinal tract, a positive result for globin therefore indicates lower gastrointestinal tract bleeding.
- the sample receiving matrix positioned behind the sample receiving port facilitates communication of the collected sample with the test strip located within the enclosure.
- the sample receiving matrix may be formed from a hydrophilic material that can absorb at least part of the collected sample delivered to the sample receiving port.
- the sample receiving matrix may be dimensioned to provide a volume sufficient to receive one or more samples and to release a quantified amount of the collected sample to the test strip to complete the test.
- the sample receiving matrix may also provide filtration of any of the solids, for example faecal solids, from the collected sample before transfer to the test strip.
- the sample receiving matrix may preferably contain one or more reagents to solubilise and buffer any analyte(s) in the sample before migrating to the test strip.
- the sample receiving matrix may also or alternatively contain one or more lytic agents to lyse and release the contents of any cells present in the collected sample.
- the sample receiving matrix may also or alternatively contain one or more surfactants to prevent non-specific binding and loss of analyte to the matrix and test strip.
- the sample receiving matrix may also or alternatively accommodate a disclosing reagent such as, for example, an anti-globin antibody conjugated to colloidal gold. As described previously, this reagent may be immobilised on the test strip.
- relocation of the reagent to the sample receiving matrix may enable longer and more uniform mixing of the sample and reagent, thereby improving reaction kinetics and potentially improving the test performance.
- the sample may be collected by dipping at least a portion of the test device into a liquid containing the sample such that the sample receiving matrix comes into contact with the liquid to thereby collect said sample.
- the sample receiving port would be located on the portion of the test device being dipped.
- the test device may be dipped one or more times into the liquid for collecting one or more samples.
- the defined saturation capacity of the sample receiving matrix enables the appropriate volume of liquid to be retained by the test strip.
- the liquid containing the sample may alternatively be collected using a sample collection apparatus for collecting the sample and delivering the sample to the sample receiving port.
- the sample collection apparatus may collect one or more samples and may deliver one or more samples to the sample receiving port.
- the liquid containing the sample may be the toilet water within which the person being tested has deposited faeces.
- the toilet water can therefore act as both the sample, and the test developer.
- the sample collection apparatus used to collect the sample may preferably be in the form of a brush or brush like apparatus having flexible or semi-flexible bristles.
- the advantage of using a brush or brush like apparatus is that it allows the collection of liquid samples within the bristles of the brush or brush-like apparatus.
- Such a sample collection apparatus is particularly applicable for use in FOBTs and FITs because it allows the collection of faecal material released from a stool located within the water of a toilet bowl.
- the bristles allow brushing around the stool to disperse any blood into the surrounding water.
- the water collected within the bristles of the brush or brush-like apparatus can act as a solvent to facilitate the liquid-conductive communication of the collected sample within the test strip.
- the brush or brush-like apparatus can be specified to collect a sufficient volume of liquid to complete the test.
- the brush or brush-like apparatus may have a liquid holding capacity equal to or greater than the defined saturation capacity of the sample receiving matrix. This ensures that the sample delivered by the brush or brush-like apparatus saturates the sample receiving matrix.
- the brush may have a liquid holding capacity less than than the defined saturation capacity of the sample receiving matrix.
- the brush may be of any suitable size. Where a large brush with capacity to deliver larger volumes of liquid is used, only one application of the liquid sample may be required. However in one embodiment, in order to enable the use and packaging of a smaller brush, it may be desirable to deliver two sequential liquid samples to the receiving port. This may also be desirable from the point of view that faecal contamination may cause an undesirable level of back ground discolouration to the test strip that may possibly obscure a borderline positive result. In order to minimize the possibility of this occurring, one may elect to use the following protocol:
- the smaller brush or brush-like apparatus may have a liquid holding capacity less than the defined saturation capacity of the sample receiving matrix. It would be appreciated by the skilled person that the total volume of liquid delivered by the smaller brushes or brush-like apparatuses is sufficient to saturate the sample receiving matrix.
- the term "brush” herein is used to denote an apparatus comprising a stem or handle, usually elongate, and a clump, bunch or group of bristles, hair or other similar flexible or semi-flexible elongate strands, laminar flaps or the like attached to the stem or handles.
- the term "brush-like apparatus” is used herein to denote an apparatus which is similar to a brush in that it includes a bunch, clump or group of bristles, hair or other similar flexible or semi-flexible elongate strands, laminar flaps or the like.
- bristles Whilst reference is made throughout the present specification to the collection of sample within the bristles of a brush or brush-like apparatus, it is to be understood that the reference to “bristles” is used to include the hairs or other similar flexible or semi-flexible elongate strands, laminar flaps or the like of a brush or brush-like apparatus.
- the detection arrangement for allowing detection of the indication of the test strip may preferably include at least one port provided in the enclosure and located over the second location of the test strip that exhibits the indication.
- a visible indication could be viewed through this port or an indication not visible to the naked eye could be detected through this port, such as using fluorimetry.
- Alternative viewing means are however also envisaged.
- a transparent section may for example be provided for the enclosure to allow for the viewing a visual indication.
- the visual indication may be for example, in the form of one or more lines extending across the exposed portion of the test strip.
- the position of the lines and/or the colour density of the or each line may provide the visual indication of the test result.
- a general assessment of the test results may be obtained by viewing the visual indication with the naked eye.
- a quantitative result may be obtained by using a viewing apparatus for measuring the colour density and distribution of the one or more lines of the visual indication.
- At least one inspection port may also preferably be provided downstream of the sample receiving port to allow observation of a visual indication confirming the flow of the collected sample through the test strip.
- a coloured dye may be used to indicate the mobilisation and flow of the collected sample through the test strip.
- the provision of the inspection port will allow the test subject to determine whether or not the collected sample has been properly transferred into the test strip, with a further sample addition being required if no flow is observed.
- the inspection port is located at the distal end of the test strip, between the control line and the absorbent. A band of water soluble dye (such as food dye) is dried onto this region of the test strip during its manufacture.
- the sample is applied to the receiving port (for example using a brush or by dipping the device into a liquid sample).
- the liquid sample is contacted with the sample port for a period of time until the band of dye is seen to be mobilised through the inspection port. Thereafter the contact can be ended.
- a brush is used, this will typically take 15-20 seconds of contacting the brush with the receiving port. If no flow is observed within 30 seconds, then another delivery of sample is required.
- the enclosure may be preferably formed from a sheet of material that may be folded to form adjacent panels of the enclosure.
- the sample receiving, viewing or detection ports may be located in at least one of the enclosure panels, for example, a front panel.
- the test strip may be secured to at least one of the enclosure panels, for example, a rear panel.
- the sheet material that could be used may include plastic or waterproof cardboard.
- An obscuring arrangement may be provided to at least hide the indication. This is likely to be of particular significance, for example, where the indication is a visual indication and it is desired that the patient not be able to read the test result. It may also be useful if the detection means, even if not visible to the naked eye, is preferably not exposed to daylight, such as a fluorescent marker.
- This arrangement may include the enclosure including at least one hinged flap for covering at least one of said ports.
- Preferably two said hinged flaps may be provided, one flap being locatable over the sample receiving port, the other flap being locatable over the viewing port.
- the flap(s) may be formed from the same sheet of material as the rest of the enclosure. The provision of a said flap over the sample receiving port provides sample containment and therefore also saves the test subject from the embarrassment of providing an exposed sample.
- said flap over the sample receiving port provides for hygiene as it seals the port and prevents faecal contamination.
- the provision of a said flap over the viewing port limits any anxiety that may arise from the test subject observing the visual indication provided by the test.
- An identifier means may preferably be provided on the enclosure that links the test subject to the test results.
- This visual indicator may preferably be in the form of a coded label that may be used to seal the flap over the sample port. The test result and the coded ID may then be captured in a digital image linking the test subject to the test result.
- a test device for testing an analyte in a collected sample comprising: an enclosure having at least one sample receiving port for receiving the collected sample; a test strip located within the enclosure, the test strip containing at least one reagent for detecting the analyte and for providing an indication showing a test result for the collected sample, the enclosure including a detection arrangement for allowing detection of the indication of the test strip; a sample receiving matrix positioned behind the at least one sample receiving port and having a defined saturation capacity, the sample receiving matrix being impregnated with reagents for pre-treatment of the sample and being in liquid-conductive communication with the test strip, wherein one or more said samples can be delivered to the at least one sample receiving port to saturate the sample receiving matrix such that a quantified amount of the sample is transferred to the test strip and an indication of the test result is effected.
- the sample can be collected by dipping the portion of the test device where the sample receiving port is located into a sample containing liquid.
- the sample may be contacted by a sample collection apparatus.
- the method and test device according to the present invention may preferably be used for detecting occult blood and/or other indicators of lower gastrointestinal disorders. This allows the method according to the present invention to be used for faecal occult blood tests and faecal immunochemical tests.
- the samples may preferably be toilet bowl water taken from the vicinity of a stool.
- the sample collection apparatus may be a brush or brush-like apparatus having flexible or semi-flexible bristles may be used to collect the sample.
- the sample may be collected within the bristles and may collect sufficient water as a solvent to complete the test.
- the volume of the sample collected may be less than, equal to or greater than the defined saturation capacity of the sample receiving matrix. Where the volume of the sample collected is less than the defined saturation capacity of the sample receiving matrix it is to be expected that two or more deliveries of sample will be applied to the sample receiving port in order to effect saturation of the sample receiving matrix.
- the present invention provides significant advantages over known FOBT and FIT systems because it allows testing of a collected sample at the time of collection, that is, the indication becomes effected automatically and rapidly once the sample is delivered to the sample receiving port since the sample is immediately enabled to wick along the full length of the test strip. The result is stable and thereby enabled to be detected at a later point in time, such as after delivery to a pathology laboratory. This then avoids known sample degradation losses of existing FOBT and FIT systems that require the collected sample to be delivered to an off-site pathology lab. Furthermore, automated test completion systems used in pathology labs to conduct the test completion are not required where a visual indication is used.
- the self-testing aspect of the test device of the present invention makes it suitable for home and field use where no laboratory facilities are available.
- the word "comprise”, and/or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
- Figure 1 is a front view of a first embodiment of a test device according to the present invention showing the sample receiving port.
- Figure 2 is a front view of the test device of figure 1 showing the viewing port.
- Figure 3(a) is a front view of an embodiment of a test device of the invention showing the first and second flaps and inspection port.
- the cellphone indicates the relative size of the device.
- Figure 3(b) is a front view of the test device with the first flap open to reveal the sample addition port and sample receiving matrix.
- Figures 4, 5 and 13 are plan views of three embodiments of the device of the present invention prior to final assembly.
- Figure 6 shows an immunochromatographic test strip according to one embodiment of the invention, including test strip, sample application (first) zone, second reagent (viewing) zone; first (disclosing) reagent (intermediate) zone, flow confirmation line of water-soluble dye.
- Figure 7 shows the inspection window in the outer panel of one embodiment of the invention, including second flap (covers the viewing port), inspection port, flow confirmation line of water-soluble dye.
- Figure 8 is a series of front views of a second embodiment of a test device according to the present invention showing the change in visual indication as a function of the test results
- Figures 9(a) and 9(b) are respectively an image showing the visual indication of the test device of Figures 4 and 5 being read using a visual detection reader and the resultant reading obtained by the reader of the visual indication,
- Figures 10(a) and 10(b) are respectively a graphical representation of dose- response curves of the buffer system and stool system. Human haemoglobin was diluted at indicated concentrations and applied to the sample receiving port. Cards were read using a digital reader and signal intensities of control line and test line were expressed as ratio metric units.
- Figure 11(a) and (b) are respectively graphical representations of analyte stability at 25°C, and analyte stability at 40°C in a buffer system.
- Human haemoglobin was diluted at indicated concentrations and applied to the sample receiving port.
- Cards were read using a digital reader and signal intensities of control line and test line were expressed as ratio metric units. Cards were stored at 25 degrees Celsius for 21 days and read at indicated intervals.
- Figure 12 is a product description table comparing the current commercially available quantitative fecal immunochemical test devices versus the device described herein DETAILED DESCRIPTION OF THE INVENTION
- FIGS 1 and 2 respectively show the assembled test device 1 according to the present invention.
- the test device 1 includes an enclosure 3 having a front panel 5.
- a sample receiving port 7 is provided on one side of the front panel 5 as shown in Figure 1.
- a viewing port 9 is provided on the other side of the front panel 5 as shown in Figure 2.
- a first flap 15 is provided to cover the sample receiving port 7, while a second flap 17 is provided to cover the viewing port 9.
- test strip 11 is accommodated within the housing 3, and a portion of the test strip 11 can be seen through the viewing port 9 in Figure 2.
- the test strip 11 contains at least one reagent for detecting an analyte within a sample being tested by the test device 1.
- a sample receiving matrix 8 is positioned behind the sample receiving port 7.
- the purpose of the sample receiving matrix 8 is to receive the sample and facilitate the transfer of a sample delivered to the sample receiving port 7 to the test strip 11.
- the sample receiving matrix 8 can contain one or more reagents to solubilise and buffer any analytes in the sample before migrating to the test strip 11.
- the matrix 8 may also or alternatively contain one or more surfactants and lytic agents to lyse and release the contents of any cells present in the collected sample.
- Figure 3(a) and 3(b) depict another embodiment of the device of the invention.
- Figure 3(a) shows the first flap 15 covers the sample receiving port, second flap 17 covers the viewing port and inspection port 19.
- Figure 3(b) shows the sample receiving port 7, sample receiving matrix 8, first flap 15, second flap 17, inspection port 19.
- the collection apparatus for collecting the sample may vary depending on the application in which the tested device 1 is being used.
- the collection apparatus may be provided by a brush or brush like apparatus (not shown) having flexible or semi flexible bristles.
- a brush or brush like apparatus (not shown) having flexible or semi flexible bristles.
- the advantage of using such a brush as a collection apparatus is that it allows for the collection of a sample from the vicinity of a stool located within the water of a toilet bowl, the brush further collecting some of the water within the bristles of the brush. This water can subsequently act as a solvent to facilitate the liquid-conductive communication of the collected sample with the test strip 11.
- the brush or brush-like apparatus can also collect sufficient water to complete the test.
- the sample is delivered to the sample receiving port 7. Any faecal solids within the sample are then filtered by the sample receiving matrix 8 before the remaining part of the sample is transferred to the test strip 1 by virtue of the liquid conductive communication with the test strip 11.
- the collected sample then migrates along the test strip 11 to areas within the strip containing the reagents (25 & 23) for detecting the analyte within the sample. In the case of FOBTs and FITs, the analyte will be
- test strip 11 furthermore provides a visual indication of the test result (23) that can be viewed through the viewing port 9.
- FIG 4 shows test device 1 prior to final assembly showing in more detail the various components of the test device 1.
- the housing 3 includes a rear panel 6, with the test strip 11 being secured to that rear panel 6. Attached to one edge of the rear panel 6 is the front panel 5 through which are respectively located the sample receiving port 7 and the viewing port 9.
- An inspection port 19 (which is not shown in Figures 1 and 2) is also optionally provided on the front panel 5 between the sample receiving port 7 and the viewing port 9. The purpose of the inspection port 19 is to allow a visual inspection of the transfer of the sample along the test strip, for example by the inclusion of a coloured dye within the test strip showing sample transfer along the test strip 11.
- the two flaps 15, 17 are attached to the opposite edge of the rear panel 6 from the front panel 5.
- the sample receiving matrix 8 is shown in Figure 4 to be significantly larger in dimension than the area of the sample receiving port 7.
- the matrix 8 is so dimensioned to provide a sufficient volume to absorb one or more collected samples, and in particular, a defined saturation capacity equal to the volume of the sample required to complete the test of the test device 1 to thereby standardise an amount of the sample used in the test.
- the test device 1 is assembled by folding the front panel 5 over the rear panel 6 thereby covering the test strip 11.
- the sample receiving part 7 is then located over a first location 21 on the test strip 11 where the sample is initially transferred from the sample receiving matrix 8.
- the viewing port 9 is located over a second location 23 on the test strip 11 where the visual indication showing the test result is shown.
- the inspection port 19 is located at an intermediate location 25 of the test strip 11 between the first and second locations 21, 23.
- Figure 5 is another embodiment of the test device and depicts front panel 5, rear panel 6, sample receiving port 7, sample receiving matrix 8, viewing port 9, test strip 11, first flap 15 (covers the sample receiving port), second flap 17 (covers the viewing port), inspection port 19, test strip first location 21 (where sample is transferred from the receiving matrix), second zone 23 (detection zone), intermediate location 25 (test strip disclosing reagent). Assembly: glue panel 5 over 6 and the right hand panel over 5.
- the method used to run the test using the test device can include the following steps:
- the brush may be sized to collect a quantity of the toilet water sample to fully saturate the sample receiving matrix 8.
- a smaller brush may be used to deliver more than one sample to fully saturate the sample receiving matrix 8.
- the faecal contamination may cause an undesirable level of background discolouration to the test strip 11 that may obscure a borderline positive test result.
- the above test method can therefore be altered by using a small brush to add a toilet water sample to the sample receiving port 19;
- the sample could be collected from the toilet water by dipping the test device 1 directly into the toilet water thereby eliminating the need for the brush or other sample collection apparatus.
- the portion of the test device 1 having the sample receiving port 7 is dipped into the toilet water to thereby saturate the underlying sample receiving matrix 8 with the toilet water sample.
- the test results can then be obtained in the same manner by viewing the visual indication provided by the test strip 11 through the viewing port 9.
- the visual indication provided by the test strip 11 may be in the form of one or more lines extending across the end of the test strip 11 viewable through the viewing port 9.
- Figures 6, 7 and 8 show a series of images of other embodiments of the test device 1 according to the present invention.
- the same reference numerals are used for the same features as the first embodiment of the test device 1 for clarity reasons.
- the visual indication may provide a quantitative result depending on the number of lines, and the colour density of the or each line.
- the visual indication for progressively increasing test values are respectively shown when looking from the left most sample to the right most sample of the image, shown in Figure 6.
- Figure 6 shows an immunochromatographic test strip according to one embodiment of the invention, including test strip (11), sample application (21) (first zone), second reagent (viewing) zone (23); first (disclosing) reagent (intermediate) zone (25), flow confirmation line of water-soluble dye (26).
- Figure 7 shows the inspection window in the outer panel of one embodiment of the invention, including second flap (covers the viewing port) (17), inspection port (19), flow confirmation line of water-soluble dye (26).
- Figure 9 shows the visual indication of a test device 1 being read by a reader that scans the visual indication of the test device 1 and provides a graphical output as shown in Figure 9(b). This graphical output can then provide a quantitative test value based on the visual indication.
- Figures 10(a) and 10(b) are respectively graphs showing a graphical representation of dose-response curves of the buffer system and stool system. Human haemoglobin was diluted at indicated concentrations and applied to the sample receiving port. Cards were read using a digital reader and signal intensities of control line and test line were expressed as ratio metric units.
- Figures 11(a) and 11(b) show the stability of the test result after storage of the device at 25 °C and 40°C.
- Human haemoglobin was diluted at indicated concentrations and applied to the sample application port. Cards were read using a digital reader and signal intensities of control line and test line were expressed as ratio metric units. Cards were stored at 25 degrees Celsius for 21 days and read at indicated intervals.
- Figure 12 is a table comparing the requirements and methods used with conventional FOBT and FIT with the test requirements and methods used for the test device 1 according to the present invention.
- the test device 1 therefore allows for the immediate testing of collected samples on site without the need to use the facilities of an off site pathology lab.
- This self-testing aspect of the test device also makes it suitable for use in the home or in the field where no laboratory facilities are available.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Clinical Laboratory Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201580057996.2A CN107148317B (en) | 2014-09-02 | 2015-08-31 | Test apparatus and method |
KR1020177008974A KR20170046179A (en) | 2014-09-02 | 2015-08-31 | Test device and method |
AU2015311609A AU2015311609A1 (en) | 2014-09-02 | 2015-08-31 | Test device and method |
BR112017004207A BR112017004207A2 (en) | 2014-09-02 | 2015-08-31 | test device and method for testing analyte on sample collected |
EP15838822.3A EP3188841A4 (en) | 2014-09-02 | 2015-08-31 | Test device and method |
CA2959680A CA2959680A1 (en) | 2014-09-02 | 2015-08-31 | Test device and method |
MX2017002795A MX2017002795A (en) | 2014-09-02 | 2015-08-31 | Test device and method. |
US15/508,314 US20170246626A1 (en) | 2014-09-02 | 2015-08-31 | Test device and method |
JP2017512045A JP6696099B2 (en) | 2014-09-02 | 2015-08-31 | Test device and method |
NZ730133A NZ730133A (en) | 2014-09-02 | 2015-08-31 | Test device and method |
IL250859A IL250859A0 (en) | 2014-09-02 | 2017-03-01 | Test device and method |
ZA2017/02133A ZA201702133B (en) | 2014-09-02 | 2017-03-27 | Test device and method |
AU2018271367A AU2018271367A1 (en) | 2014-09-02 | 2018-11-30 | Test device and method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462044804P | 2014-09-02 | 2014-09-02 | |
US62/044,804 | 2014-09-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016033646A1 true WO2016033646A1 (en) | 2016-03-10 |
Family
ID=55438920
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU2015/050510 WO2016033646A1 (en) | 2014-09-02 | 2015-08-31 | Test device and method |
Country Status (13)
Country | Link |
---|---|
US (1) | US20170246626A1 (en) |
EP (1) | EP3188841A4 (en) |
JP (1) | JP6696099B2 (en) |
KR (1) | KR20170046179A (en) |
CN (1) | CN107148317B (en) |
AU (2) | AU2015311609A1 (en) |
BR (1) | BR112017004207A2 (en) |
CA (1) | CA2959680A1 (en) |
IL (1) | IL250859A0 (en) |
MX (1) | MX2017002795A (en) |
NZ (1) | NZ730133A (en) |
WO (1) | WO2016033646A1 (en) |
ZA (1) | ZA201702133B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9918702B2 (en) | 2014-08-12 | 2018-03-20 | Nextgen Jane, Inc. | System and method for monitoring health based on collected bodily fluid |
US11446011B2 (en) | 2016-04-13 | 2022-09-20 | Nextgen Jane, Inc. | Sample collection and preservation devices, systems and methods |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI674408B (en) * | 2018-08-16 | 2019-10-11 | 準訊生醫股份有限公司 | Fecal occult blood detecting device and method |
CN110836889B (en) * | 2018-08-16 | 2022-07-29 | 吴智良 | Fecal occult blood detection device and method |
WO2021202110A1 (en) * | 2020-03-30 | 2021-10-07 | Clinical Genomics Pty Ltd | Lateral flow device for detecting colorectal cancer |
DE102023118482B3 (en) | 2023-07-12 | 2024-05-16 | Protzek Biotec Gmbh | Device and method for the visual detection of analytes in a saliva sample |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999056103A1 (en) * | 1998-04-28 | 1999-11-04 | Enterix Inc. | Sample collection method |
US6103536A (en) * | 1997-05-02 | 2000-08-15 | Silver Lake Research Corporation | Internally referenced competitive assays |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4675160A (en) * | 1986-01-28 | 1987-06-23 | Warner-Lambert Company | Occult blood test monitor |
US4810470A (en) * | 1987-06-19 | 1989-03-07 | Miles Inc. | Volume independent diagnostic device |
US5064541A (en) * | 1989-04-07 | 1991-11-12 | Abbott Laboratories | Devices and methods for the collection of a predetermined volume of plasma or serum |
IL135082A0 (en) * | 1997-10-06 | 2001-05-20 | Enterix Inc | Apparatus and method for analyte detection |
AUPP713498A0 (en) * | 1998-11-17 | 1998-12-10 | Chandler, Howard Milne | A method of detecting blood |
DK1175511T3 (en) * | 1999-04-13 | 2006-01-09 | Agres Ltd | Methods and test kits for collecting and storing biological samples |
US20030124618A1 (en) * | 2001-12-04 | 2003-07-03 | Lattec I/S | Device for analysing analyte compounds and use hereof |
RU2006139643A (en) * | 2004-04-09 | 2008-05-20 | Ресерч Тинк Тэнк, Инк. (Us) | METHOD FOR COLLECTING, STORING AND TRANSPORTING BIOLOGICAL SAMPLES AND DEVICE FOR ITS IMPLEMENTATION |
EP1619502B1 (en) * | 2004-07-22 | 2009-07-22 | Immunostics, Inc. | Fecal occult blood testing device and method |
US20070122819A1 (en) * | 2005-11-25 | 2007-05-31 | Industrial Technology Research Institute | Analyte assay structure in microfluidic chip for quantitative analysis and method for using the same |
US10209265B2 (en) * | 2007-04-19 | 2019-02-19 | Quest Diagnostics Investments Incorporated | Chain of custody forms and methods |
US8323466B2 (en) * | 2008-12-05 | 2012-12-04 | Nanoivd, Inc. | Microfluidic-based lab-on-a-test card for a point-of-care analyzer |
WO2010132453A2 (en) * | 2009-05-11 | 2010-11-18 | Nexus Dx, Inc. | Methods and compositions for analyte detection |
WO2013102067A1 (en) * | 2011-12-28 | 2013-07-04 | Bayer Healthcare Llc | Analyte monitor |
CA2867125C (en) * | 2012-03-01 | 2020-04-28 | Quidel Corporation | Interactive test device and apparatus with timing mechanism |
GB201220350D0 (en) * | 2012-11-12 | 2012-12-26 | Mode Diagnostics Ltd | Personal test device |
-
2015
- 2015-08-31 EP EP15838822.3A patent/EP3188841A4/en not_active Withdrawn
- 2015-08-31 NZ NZ730133A patent/NZ730133A/en not_active IP Right Cessation
- 2015-08-31 KR KR1020177008974A patent/KR20170046179A/en unknown
- 2015-08-31 JP JP2017512045A patent/JP6696099B2/en not_active Expired - Fee Related
- 2015-08-31 BR BR112017004207A patent/BR112017004207A2/en not_active Application Discontinuation
- 2015-08-31 WO PCT/AU2015/050510 patent/WO2016033646A1/en active Application Filing
- 2015-08-31 US US15/508,314 patent/US20170246626A1/en not_active Abandoned
- 2015-08-31 MX MX2017002795A patent/MX2017002795A/en unknown
- 2015-08-31 CA CA2959680A patent/CA2959680A1/en not_active Abandoned
- 2015-08-31 CN CN201580057996.2A patent/CN107148317B/en active Active
- 2015-08-31 AU AU2015311609A patent/AU2015311609A1/en not_active Abandoned
-
2017
- 2017-03-01 IL IL250859A patent/IL250859A0/en unknown
- 2017-03-27 ZA ZA2017/02133A patent/ZA201702133B/en unknown
-
2018
- 2018-11-30 AU AU2018271367A patent/AU2018271367A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6103536A (en) * | 1997-05-02 | 2000-08-15 | Silver Lake Research Corporation | Internally referenced competitive assays |
WO1999056103A1 (en) * | 1998-04-28 | 1999-11-04 | Enterix Inc. | Sample collection method |
Non-Patent Citations (1)
Title |
---|
See also references of EP3188841A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9918702B2 (en) | 2014-08-12 | 2018-03-20 | Nextgen Jane, Inc. | System and method for monitoring health based on collected bodily fluid |
US11446011B2 (en) | 2016-04-13 | 2022-09-20 | Nextgen Jane, Inc. | Sample collection and preservation devices, systems and methods |
US11864740B2 (en) | 2016-04-13 | 2024-01-09 | Nextgen Jane, Inc. | Sample collection and preservation devices, systems and methods |
Also Published As
Publication number | Publication date |
---|---|
CN107148317A (en) | 2017-09-08 |
ZA201702133B (en) | 2019-08-28 |
IL250859A0 (en) | 2017-04-30 |
KR20170046179A (en) | 2017-04-28 |
NZ730133A (en) | 2018-06-29 |
JP6696099B2 (en) | 2020-05-20 |
US20170246626A1 (en) | 2017-08-31 |
EP3188841A1 (en) | 2017-07-12 |
CN107148317B (en) | 2020-02-18 |
JP2017525975A (en) | 2017-09-07 |
EP3188841A4 (en) | 2018-08-22 |
CA2959680A1 (en) | 2016-03-10 |
BR112017004207A2 (en) | 2017-12-12 |
MX2017002795A (en) | 2018-01-23 |
AU2018271367A1 (en) | 2018-12-20 |
AU2015311609A1 (en) | 2017-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018271367A1 (en) | Test device and method | |
CA1289857C (en) | Method and device for collecting and testing for fecal occult blood | |
CA1309330C (en) | Method and device for collecting and testing for fecal occult blood | |
US8062901B2 (en) | Devices and methods for sample collection and analysis | |
US20070092401A1 (en) | Devices and methods for sample collection and analysis | |
US8927262B2 (en) | Ovulation predictor test | |
US20090226928A1 (en) | Method and kit for detecting an analyte in a sample | |
US20090117660A1 (en) | Devices and methods for sample collection and analysis | |
JP2007511767A (en) | High-speed sample analysis and storage device and method of use | |
JP2018533745A (en) | Fecal sample collection, sampling and diagnostic means and methods thereof | |
WO2006116917A2 (en) | Devices and methods for sample collection and analysis | |
US20070166191A1 (en) | Device and method for fecal testing | |
TW201215365A (en) | Fecal occult blood testing device | |
WO2005007067A2 (en) | Sanitary and compact fecal occult blood collector | |
CN217084994U (en) | Echinococcus antibody immunochromatography detection card | |
WO2021202110A1 (en) | Lateral flow device for detecting colorectal cancer | |
JP3561588B2 (en) | Immunological test equipment | |
CN116718775B (en) | Composition, test paper and method for detecting colorectal cancer | |
JP3717936B2 (en) | Sample collector | |
JP3717936B6 (en) | Sample collector | |
WO2024016048A1 (en) | Sampling apparatus and method and testing kit and method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15838822 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017512045 Country of ref document: JP Kind code of ref document: A Ref document number: 2959680 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 250859 Country of ref document: IL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15508314 Country of ref document: US Ref document number: MX/A/2017/002795 Country of ref document: MX |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112017004207 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 20177008974 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015838822 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015838822 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015311609 Country of ref document: AU Date of ref document: 20150831 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112017004207 Country of ref document: BR Kind code of ref document: A2 Effective date: 20170302 |